Research graph
References from Effect of erlotinib and celecoxib as short-course neoadjuvant therapy in operable oral cavity squamous cell carcinoma: a randomized controlled window-of-opportunity trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck
10.1158/1078-0432.ccr-03-0677 · 2004 · External reference
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck
10.1200/jco.2003.10.051 · 2003 · External reference
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck
2016 · External reference
Integrative analysis of multi-omics data identified EGFR and PTGS2 as key nodes in a gene regulatory network related to immune phenotypes in head and neck cancer
10.1158/1078-0432.ccr-19-3997 · 2020 · External reference
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase Ib and pharmacokinetic study
10.1158/1940-6207.capr-13-0215 · 2013 · External reference
Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer
10.1056/nejmoa2415434 · 2025 · External reference
10.1158/1078-0432.ccr-12-3149
10.1158/1078-0432.ccr-12-3149 · External reference
Tumor growth rate of invasive breast cancers during wait times for surgery assessed by ultrasonography
10.1097/md.0000000000004874 · 2016 · External reference
Time-to-treatment in oral cancer: causes and implications for survival
10.3390/cancers13061321 · 2021 · External reference
Mortality due to cancer treatment delay: systematic review and meta-analysis
2020 · External reference
Delay in seeking specialized care for oral cancers: Experience from a tertiary cancer center
10.4103/0019-509x.137934 · 2014 · External reference
10.4322/acr.2021.251
10.4322/acr.2021.251 · External reference
Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma
10.2174/156800909790192437 · 2009 · External reference
Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer
10.1002/cncr.29480 · 2015 · External reference
